Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC and Systemic Chemotherapy for Unresectable Peritoneal Metastases from Colorectal Cancer
NCT03398512Terminated
- Sponsor
- Wuhan University
- Start
- Feb 2018
- Primary completion
- Mar 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of raltitrexed, oxaliplatin and capecitabine in colorectal cancer (CRC) and Peritoneal metastases, sponsored by Wuhan University. Primary endpoint: Radical Resection Rate at 3 months. Started Feb 2018; status: terminated.
02
Drugs
raltitrexedoxaliplatincapecitabine
03
Conditions
colorectal cancer (CRC)Peritoneal metastases
Beyond the preview
Go deeper on NCT03398512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398512.